Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives -…

SALT LAKE CITY, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new technology and healthcare leaders who recently joined the company as well as key promotions to drive critical business functions, transformation and growth initiatives.

With the addition of new leaders from other industry leading enterprises, we continue to augment our strong bench of talent across a range of functions that will accelerate the execution of our strategy with disciplined process management and proven expertise, said Paul J. Diaz, president and CEO of Myriad Genetics. We are pleased to welcome new teammates who share the passion for our mission to improve health and wellbeing for all as we continue to recruit and promote top talent from outside and inside our company.

The following Myriad Genetics leaders are assuming broader roles:

Kevin R. Haas is promoted to Chief Technology Officer, reporting directly to Diaz, responsible for engineering, data and analytics, genetic laboratory software, and improving the customer experience through tech-enabled, customer-centric commercial capabilities. Since joining Myriad in 2013, Haas has served in senior level leadership roles across research and development, bioinformatics, engineering and technology.

Faith Zaslavsky is promoted to president of Myriad Oncology which offers genetic testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs. Since 2019, Zaslavsky has served as general manager of this business unit, overseeing products including Myriad myRisk Hereditary Cancer, myChoice CDx companion diagnostic, and EndoPredict breast cancer tests. Over her 21-year career at Myriad, Zaslavsky has held progressively responsible sales, strategic account management and leadership roles.

New leaders recently joining Myriad include:

Maggie Ancona, senior vice president, Enterprise Transformation and Program Management Office. She reports directly to Diaz, managing a broad range of enterprise-wide transformation initiatives and workstreams with a focus on operational excellence. Ancona previously led Global Transformation and Program Management at Hewlett Packard (HP) and Dell Technologies where she oversaw business transformation strategy, executed large-scale programs and cost management efforts, while retooling digital infrastructure for the future.

David Hammer, senior vice president, Revenue Cycle Management, has overall accountability for the process, including functions that contribute to the capture, management, and collection of diagnostic-service revenue and related areas designed to improve the customer experience. He previously held senior revenue cycle management roles at RGP Healthcare, MedAssets, and Accenture. Hammer also serves on the Board of Advisors of the University of Florida's College of Public Health and Health Professions.

Chris Williamson, senior vice president, Information Systems and Security. Williamson previously led all facets of information technology, infrastructure, business intelligence and operations for Data2Logistics, a leading data-driven freight, audit and payment services company. A retired Naval Officer, Williamson served in the White House (executive office of the President) for the Technology Assessment Center and Information Technology Working Group.

Edward Gala, senior vice president, Enterprise Marketing Communications, responsible for strategic public relations, employee and executive communications, and overall brand marketing. Gala previously held global marketing and communications leadership positions at Xerox and Philips where he played a key role in brand transformation and positioning, business-to-business and consumer marketing across corporate, business, market and product groups.

Karen Renner, vice president, Digital Marketing, responsible for digital infrastructure, patient lead nurturing, conversion and support for products including Myriads myRisk Hereditary Cancer test and related digital initiatives across Womens Health and Oncology. Karen previously served as the global digital and eBusiness leader at Nestle Purina and brings prior digital agency experience with leading consumer product accounts at VMLY&R.

Jackie Zou, vice president, Business Development, responsible for supporting new growth opportunities, including the development and execution of transactions such as divestitures, potential mergers and acquisitions (M&A), and new partnerships. Zou held senior roles in strategy and finance, at Western Digital Corporation (WD), a global data technology, storage and digital content company, where she planned and executed merger, acquisition and divestiture transactions, joint venture initiatives, strategic partnerships and business development. Zou previously worked at Symantec, ZS Associates and Goldman Sachs.

Justin Hunter, vice president, Corporate Legal Affairs, responsible for providing legal counsel and support for corporate governance, SEC reporting, M&A, and related matters. Hunter previously served as senior legal counsel for Parsley Energy where he was responsible for SEC reporting and compliance, acquisitions and divestitures, and corporate governance. Previously he worked at Vinson & Elkins LLP and as a law clerk to Vice Chancellor Noble on the Delaware Court of Chancery.

Top Place to WorkMyriad Genetics recently was named among the Top Places to Work in Energages Top Workplaces USA list for 2021. The company ranked number one in the Health Industry category and earned additional awards in Cultural Excellence and Innovation & Leadership. Myriad employs more than 2,800 people across the United States and in several countries around the globe. To learn more about career opportunities at Myriad, visit our website.

About Myriad GeneticsMyriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to driving key business functions, transformation and growth initiatives and accelerating the execution of Myriads strategy with disciplined process management and proven expertise; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

View post:
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives -...